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Abstract
We aimed to assess the status of naturally occurring CD4+ and CD8+ T cell responses to a tumour associated antigen,
Mesothelin, in patients with pancreatic carcinoma and study the effects of elevated IL-10 on Mesothelin-specific T cell
responses. For that sake, short term T cell lines were generated from PBMCs of 16 healthy controls, 15 patients with benign
pancreatic diseases and 25 patients with pancreatic carcinoma and Mesothelin-specific CD4+ and CD8+ T cell responses
were analysed using intracellular cytokine assays for IFN-c. Plasma levels of IL-10 and Mesothelin were measured using
cytometric bead array and ELISA assay, respectively. The blocking assays were performed to assess the effects of IL-10 on
Mesothelin-specific T cell responses. Here, we demonstrate that the plasma levels of Mesothelin and IL-10 are significantly
increased in patients with pancreatic carcinoma. Additionally, we found that (a) Mesothelin-specific T cell responses are
significantly expanded in cancer patients (p = 0.0053), (b) the multifunctional CD4+ T cell response is directed toward a
broad repertoire of epitopes within the Mesothelin protein. (c) Mesothelin-specific CD4+ T cell response is directly inhibited
by elevated IL-10 in cancer patients. These data provides evidence for the use of Mesothelin as an immunogen for tumour-
specific T cell response.
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Introduction
Pancreatic cancer (PC) is a significant cause of tumour-related
death worldwide, which ranks the 10th commonest cancer in men
and the 11th in women [1], and stands as the 4th leading cause of
cancer-linked mortality in both the USA [2] and Europe [3].
Important risk factors for this disease include age, smoking,
obesity, family history chronic pancreatitis and diabetes [4–9].
Early diagnosis may increase the chance of curative resection of
pancreatic cancer [10]. Surgical resection such as pancreaticodu-
odenectomy (Whipple technique) is suitable for patients with
localized pancreatic cancers [11], but is only appropriate for up to
15–20% of patients [12]. Nearly 30% of PC patients have locally
advanced disease by the time of diagnosis, with a further 50%
patients carrying metastatic deposits [13]. Gemcitabine or
folfirinox-based regimens are the treatment of choice for
unresectable or metastatic pancreatic cancer and are also used
in the neoadjuvant/adjuvant setting [14–16], yet, over the last 30
years there has been little improvement in survival of PC patients
with an overall 5 year survival 2–6% [2]. Thus, innovative
diagnostic and therapeutic strategies are urgently required.
Cell-based antitumor immunotherapy is a promising strategy
for the treatment of some cancers and it is also being considered
for the treatment of pancreatic cancer. Activated CD8+ T cells
have been shown to migrate to the tumour microenvironment and
cause lysis of tumour cells mediated by granzyme B, perforin or
Fas[17]. Effector Th1 type helper CD4+ T cells with the ability to
secrete IFN-c and TNF-a can act as regulators in anti-tumour
immunity and provide ‘help’ for the development of potent anti-
tumour CTLs [18,19] by supporting their expansion and memory
development. Activated tumour-infiltrating lymphocytes are ob-
served in many types of tumours and relate to better prognosis
[20,21]. Successful antitumor T cells responses rely on recognition
of tumour-associated antigens (TAAs) by T cells [22].
Mesothelin (MSLN) is a 40k-Da GPI-anchored glycoprotein
expressed on the cell surface, which can be released by
Phospholipase C [23]. In normal cells, MSLN expression is
limited to the surface of a single layer of mesothelial cells located in
pleura and peritoneum [24]. MSLN is overexpressed in many
types of cancers, including ovarian, pancreatic/biliary, lung
cancers and mesotheliomas [25]. Using a monoclonal antibody
(5B2) directed against MSLN, expression was identified in 91–
100% of pancreatic cancer tissue [26–28]. In addition, some
studies also reported elevated levels of soluble MSLN in
mesothelioma, ovarian cancer and pancreatic cancer [29–31].
The biological function of MSLN has not been clearly understood,
but a MSLN knock-out mouse model showed no clear phenotypic
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Table 1. Pancreatic cancer patients’ information.
ID of PC
patients Age (year) Gender Histological diagnosis Grade
Plasma mesothelin (ng/
ml)
PC01 63 F adenocacinoma IVB 21.8
PC02 77 M Adenocacinoma with squamous differenciation IVB 21.6
PC03 47 M PDAC III 74.0
PC04 80 M Epithelial neoplasia n.a. 53.4
PC05 66 F PDAC n.a. 13.8
PC06 80 F PDAC n.a. 20.1
PC07 72 M adenocacinoma n.a. 13.4
PC08 54 F Poorly differentiated ademocarcinoma III n.a.
PC09 41 M adenocacinoma n.a. 13.3
PC10 71 F morderately differentiated adenocarcinoma II 34.9
PC11 86 F adenocacinoma IVA
PC12 83 F adenocacinoma II 27.3
PC13 n.a. F moderatedly differentiated adenocarcinoma n.a. 42.3
PC14 60 F adenocacinoma III 26.4
PC15 80 F morderately differentiated adenocarcinoma III 52.3
PC16 74 M PDCA (not tolerate to chem.) IVB 75.78
PC17 78 M PDCA (in chem.) IVB 27.034
PC18 67 F postoperative ademocacinoma Disease-free 18.17
PC19 94 F adenocacinoma IVB 40.1
PC20 76 M PDAC IVA 38.9
PC21 69 M adenocacinoma IVB 27.6
PC22 65 M Recurrent adenocacinoma IVA 100.956
PC23 61 M Recurrent adenocacinoma IVA 30.7
PC24 41 M poor differentiation p ampilay cancer IV 18.2
PC25 69 F adenocacinoma III 32.7
doi:10.1371/journal.pone.0088133.t001
Table 2. Patients Demographic Information (Benign disease patients).
ID of control patients Age (year) Gender Diagnosis Plasma Mesothelin (ng/ml)
CON01 40 M Chronic pancreatitis 56.7
CON02 50 F Acute pancreatitis 31.6
CON03 77 F mucinous cystic lesion 11.5
CON04 54 F benign lesion in pancreas 17.1
CON05 32 F recurrent pancreatitis N.A.
CON06 50 F Acute pancreatitis secondary to biliary duct stone N.A.
CON07 63 M Cystic disease 33.9
CON08 41 M Chronic pancreatitis 62.5
CON09 82 M Cystic disease 18.2
CON10 n.a. F Chronic pancreatitis 7.6
CON11 46 F Chronic pancreatitis 11.3
CON12 24 M Cystic disease, acute pancreatitis 0
CON13 59 F Recurrent pancreatitis 31.0
CON14 50 M Necrotic pancreatitis 19.1
CON15 53 F Cystic disease N.A.
doi:10.1371/journal.pone.0088133.t002
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or functional defects during development or with reproduction
ability [32]. However, in mouse models of pancreatic cancer,
MSLN overexpression was shown to promote metastasis and
proliferation of tumour cells [33]. In animal models, the induction
of anti-Mesothelin CD8+ T cell responses resulted in the reduction
in tumour volume and prolonged survival in an orthotopic PC
mouse model [33,34], suggesting that MSLN is a tumour rejection
antigen for pancreatic carcinoma. A pilot study further illustrated
that an allogeneic GM-CSF secreting pancreatic cancer cells
vaccine could stimulate MSLN specific T cells and that was
favourable in gemcitabine-resistant advanced pancreatic cancer
patients. Furthermore, this study demonstrated that MSLN
specific CD8+ T cell response could be induced via cross
presentation of tumour antigens in an immunotherapy approach
that recruits antigen presenting cells to the site of vaccination [35].
Thus, MSLN is a possible biomarker for pancreatic cancer and
target for T-cell based immunotherapy. There is very little
information on naturally occurring MSLN-specific T cell respons-
es in cancer patients. This study aimed to identify and functionally
characterise MSLN-specific T cell responses and establish whether
the elevation of immune-regulatory cytokines such as IL-10 can
modulate this response.
Materials and Methods
Patients
The study was approved by the Central London REC 3
Research Ethics Committee, and all patients gave written,
informed consent. The trial was run in accordance with the
Declaration of Helsinki. Blood samples were obtained from
patients at University College Hospital, Royal Free Hospital
(UCL, London, UK), and Charing Cross Hospital (IC, London,
UK). Mononuclear cells were isolated from peripheral blood
samples of patients with pancreatic cancer (Table 1), benign
pancreatic disease (Table 2) and age- and sex-matched healthy
donors. Pancreatic carcinoma (PC) diagnosis was confirmed by
standard cytopathology or histopathology after biopsy. The
clinical staging of patients with pancreatic carcinoma was
Table 3. Mesothelin-derived peptides.
Amino acid start pool sequence Amino acid start pool sequence
1 1 MALPTARPLLGSCGT 321 4 WELEACVDAALLATQ
11 1 GSCGTPALGSLLFLL 331 4 LLATQMDRVNAIPFT
21 1 LLFLLFSLGWVQPSR 341 4 AIPFTYEQLDVLKHK
31 1 VQPSRTLAGETGQEA 351 4 VLKHKLDELYPQGYP
41 1 TGQEAAPLDGVLANP 361 4 PQGYPESVIQHLGYL
51 1 VLANPPNISSLSPRQ 371 4 HLGYLFLKMSPEDIR
61 1 LSPRQLLGFPCAEVS 381 4 PEDIRKWNVTSLETL
71 1 CAEVSGLSTERVREL 391 4 SLETLKALLEVNKGH
81 1 RVRELAVALAQKNVK 401 5 VNKGHEMSPQAPRRP
91 1 QKNVKLSTEQLRCLA 411 5 APRRPLPQVATLIDR
101 2 LRCLAHRLSEPPEDL 421 5 TLIDRFVKGRGQLDK
111 2 PPEDLDALPLDLLLF 431 5 GQLDKDTLDTLTAFY
121 2 DLLLFLNPDAFSGPQ 441 5 LTAFYPGYLCSLSPE
131 2 FSGPQACTRFFSRIT 451 5 SLSPEELSSVPPSSI
141 2 FSRITKANVDLLPRG 461 5 PPSSIWAVRPQDLDT
151 2 LLPRGAPERQ RLLPA 471 5 QDLDTCDPRQLDVLY
161 2 RLLPAALACWGVRGS 481 5 LDVLYPKARLAFQNM
171 2 GVRGSLLSEADVRAL 491 5 AFQNMNGSEYFVKIQ
181 2 DVRALGGLACDLPGR 501 6 FVKIQSFLGGAPTED
191 2 DLPGRFVAESAEVLL 511 6 APTEDLKALSQQNVS
201 3 AEVLLPRLVSCPGPL 521 6 QQNVSMDLATFMKLR
211 3 CPGPLDQDQQEAARA 531 6 FMKLRTDAVLPLTVA
221 3 EAARAALQGGGPPYG 541 6 PLTVAEVQKLLGPHV
231 3 GPPYGPPSTWSVSTM 551 6 LGPHVEGLKAEERHR
241 3 SVSTMDALRGLLPVL 561 6 EERHRPVRDWILRQR
251 3 LLPVLGQPIIRSIPQ 571 7 ILRQRQDDLDTLGLG
261 3 RSIPQGIVAAWRQRS 581 7 TLGLGLQGGIPNGYL
271 3 WRQRSSRDPSWRQPE 591 7 PNGYLVLDLSMQEAL
281 3 WRQPERTILRPRFRR 601 7 MQEALSGTPCLLGPG
291 3 PRFRREVEKTACPSG 611 7 LLGPGPVLTVLALLL
301 4 ACPSGKKAREIDESL 616 7 PVLTVLALLLASTLA
311 4 IDESLIFYKKWELEA
doi:10.1371/journal.pone.0088133.t003
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determined using the WHO histological classification of tumours
of the exocrine pancreas [36].
Mesothelin ELISA
Plasma Mesothelin (MSLN) concentration was measured by
Quantikine (R&D Systems Europe, Ltd, Abingdon, UK) - a
validated double determinant sandwich ELISA. Briefly, 5 ml
plasma (1 in 10 diluted in assay diluent) was incubated in MSLN
antibody pre-coated microplates at room temperature for 2 hours.
After washing unbound elements, a MSLN-specific enzyme-linked
monoclonal antibody was added and incubated for a further
2 hours, prior to adding substrate for 30 minute incubation. A
microplate reader was used to determine optical density after
stopping the development reaction.
Cytometric bead array (CBA)
Concentrations of IL-10 in plasma samples were determined
using the BD cytometric bead array human inflammatory
cytokines kit (BD Biosciences, CA, US). In brief, beads coated
with antibodies binding the above-mentioned cytokines were
incubated with plasma for 3 hours in order to ‘capture’ cytokines.
The samples were analysed by FACSCanto II flow cytometer (BD
Biosciences) in the FL-3 channel using FCAP Array Software v3.0
(BD Biosciences).
Peptide library
Peptides corresponding to the sequence of MSLN were
synthesized by Mimotopes Pty Ltd. (Clayton Victoria, Australia).
Fifteen amino acid long peptides, overlapping by five amino acids,
were pooled into 7 peptide pools. Details of amino acid sequences
are given in Table 3.
T cell culture and intracellular cytokine staining assay
PBMCs were re-suspended at a concentration of 1.56106/mL
in RPMI 1640, 10% heat-inactivated FCS (Life technologies,
Grand Island, NY), and 1% penicillin plus streptomycin (Sigma-
Aldrich, St. Louis, MO). PBMCs were stimulated with peptide
pools at a final concentration of 2 mmol/ mL for each individual
peptide or irrelevant peptides, as negative control. We have
selected the peptide concentration used in this study based on our
previous T epitope mapping studies and reports from other
researchers in the field. Recombinant IL-2 (25 UL/mL) was
added on the 1st day of culture and the cells were analysed after a
total of 9-10 days culture. T-cell lines were re-stimulated with the
same peptide pools for a further 5 hours in the presence of
Brefeldin A. Cells were surface stained with anti-CD4 and anti-
CD8 antibodies (BD PharMingen, Cowley, United Kingdom),
then permeabilized and fixed using formaldehyde and saponin.
After fixing, the cells were stained for intracellular cytokines with
FITC-conjugated anti IFN-c, FITC-conjugated anti-IL-2, and PE-
conjugated anti-TNFa (R&D Systems, Abingdon, United King-
dom).
Individual peptide simulation experiments
In some patients where MSLN-specific CD4+ T cell responses
were observed and surplus PBMC were available for further
testing, we performed additional experiments to identify the
cognate peptides. PBMCs were cultured with responding peptide
pool and rIL-2 in RPMI (as before) for 9-10 days. On day 9 or 10,
these cells were further cultured for 5 hours in the presence of
individual peptides from the relevant peptide pool, or with
irrelevant peptide as control. The T cells were then stained with
anti-CD4, anti-CD8 and IFN-c prior to analysis by flow cytometry
(as before).
IL-10 blockade
We performed IL-10 blocking assays during peptide stimulation
of PBMC from some patients that we had obtained larger number
of cells. MSLN-specific T cell lines were generated in the presence
of blocking antibodies to anti-IL10 (5 mg/mL) (eBioscience) and
anti-IL-10R (10 mg/mL). On day 4, 150 ml supernatant was
Figure 1. PlasmaMesothelin concentrations in different groups
of patients. This figure shows plasma Mesothelin concentrations in
pancreatic cancer patients (n = 32), patients with benign pancreatic
disease (n = 13), or healthy controls (n = 13) detected using an ELISA
assay for human Mesothelin. The horizontal line displays the median
value for each group. Mann-Whitney U test was used to compare the
levels of plasma Mesothelin in different groups of patients.
doi:10.1371/journal.pone.0088133.g001
Figure 2. Plasma IL-10 concentration. This figure displays the
plasma IL-10 levels observed in the different disease groups: pancreatic
cancer patients (n = 34), patients with benign pancreatic disease
(n = 15), or healthy controls (n = 13). Median values of each group
are presented by the horizontal lines. The plasma IL-10 levels was
elevated in pancreatic cancer patients, with a median at 2.45 pg/mL
(n = 34), which was significantly higher than both healthy donors
(P,0.001), whose median was 1.10 pg/mL (n = 13), and benign
pancreatic disease patients (P = 0.047), with median plasma IL-10
concentration at 1.99 pg/mL, (n = 15). There is no significant difference
between normal volunteers and patients with benign pancreatic
disease in the regards of plasma IL-10 levels (P = 0.14).
doi:10.1371/journal.pone.0088133.g002
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removed, and replenished with 150 ml of fresh medium with
additional anti-IL-10 antibody 5 mg/ml, IL-10Ra (10 mg/ml), as
well as IL-2 (25 UL/mL). The re-stimulation and intracellular
cytokine staining at day 9–10 was performed as described above.
Statistical analysis
Statistical analysis was performed using SPSS for windows 17.0.
The Mann-Whitney U test (for 2 groups) and Kruskal-Wallis test
(for 3 groups) analyses were applied to compare the plasma levels
of MSLN and the 6 cytokines in pancreatic cancer patients
compared to control subjects. The Chi-squared test was used to
determine statistical significance of MSLN-specific CD4+ and
CD8+ T cell response rates in cancer and control groups. The
Spearman rank coefficient was utilized to check the correlation
between plasma MSLN levels and T cell response levels. Kruskal-
Wallis test was employed to analyse the levels of T cell response
between PC, benign pancreatic disease patients and healthy
volunteers. A significant interval was defined at 95%, or two tailed
p-value # 0.05.
Results
Plasma MSLN levels are increased in pancreatic cancer
patients
A sandwich enzyme immunoassay using monoclonal antibody
directed against MSLN was used to detect circulating MSLN
levels. The method is described in detail in the Material and
Methods section. Of a total 13 healthy controls, 11 (85%) had
MSLN levels less than 20 ng/ml, with the median value at
12.0 ng/ml (ranged from 0 ng/ml to 32.2 ng/ml). Compared to
healthy controls, the plasma MSLN levels were significantly
elevated in patients with benign pancreatic disease (n = 13,
p,0.05) (Figure 1), where the median concentration was
19.1 ng/ml (range: 0 to 62.5 ng/ml). The median plasma MSLN
concentration in 32 pancreatic cancer patients was 27.4 ng/ml,
with the minimum of 3.7 ng/ml and maximum of 101 ng/ml.
Additionally, statistically significant differences were observed
between soluble MSLN levels of PC patients and that of healthy
volunteers (p,0.001), but no significant differences between the
plasma MSLN concentration in the cancer patients and that of the
benign pancreatic disease patients (p = 0.17) (Figure 1). Subset
analysis between metastatic pancreatic cancer (stage IVB) com-
pared to patients with benign pancreatic disease demonstrated no
significant difference in soluble MSLN concentration between
these groups (data not shown). These results suggest that
circulating MSLN levels are significantly increased in patients
with benign and malignant pancreatic disease.
Plasma IL-10 levels are increased in pancreatic cancer
patients
A cytometric bead array (CBA) assay was used to determine the
concentration of IL-10 in plasma samples (as described in material
and method section). IL-10 concentration was determined by flow
cytometry after the generation of a standard curve derived from
serial dilutions. Plasma IL-10 concentrations were significantly
higher in patients with benign pancreatic disease compared to
normal controls (p,0.001). Figure 2 shows the plasma IL-10 levels
observed in the different disease groups (normal, benign disease
and PC). Statistical comparisons were made using Mann-Whitney
Figure 3. Mesothelin (MSLN)-specific IFN-c producing CD4+ and
CD8+ T cell response. Representative FACs plots of IFN-c production
by CD4+ and CD8+ T cells from short term T cell lines following re-
stimulation with MSLN-derived peptides or an irrelevant peptide are
shown. The production of MSLN-specific IFNcby CD4+ and CD8+ T cells
was assessed using intracellular cytokine staining assay. Numbers in the
top right quadrants are the percentage of cytokine-producing cells
within viable CD4+ or CD8+ T cells (A). The number of peptide pools (7
peptide pools in total) that stimulated IFN- c production by CD4+ or
CD8+ T cells isolated from 16 healthy donors, 15 patients with benign
pancreatic disease and 25 patients with pancreatic carcinoma are
shown (B). An immunological response was defined as a 2-fold increase
in the frequency of cytokine-producing cells above control peptides/
pools.
doi:10.1371/journal.pone.0088133.g003
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U test to determine the differences within the 3 subject groups. As
we can see, plasma IL-10 concentrations was significantly
increased in pancreatic cancer patients (median= 2.45 pg/mL,
n= 34), with comparison to both benign pancreatic disease
patients (median= 1.99 pg/mL, n= 15, P= 0.047), and normal
donors (median= 1.10 pg/mL, n= 13, p,0.001). No significant
difference between normal volunteers and patients with benign
pancreatic disease had been seen in the regards of plasma IL-10
levels (P = 0.14).
Detection of circulating MSLN-specific CD4+ and CD8+ T
cells in cancer and benign patients
Patients’ demographics are described in Table 1 and 2. The
clinical stage of the pancreatic cancer was known in 19, and 89%
(17 out of 19) had advanced stage disease (stage III/IV). Short-
term T cell lines were generated in the presence of MSLN-derived
peptide pools (Table 3) and rIL-2 from PBMCs of 25 patients with
pancreatic cancer (PC01-PC25), 15 patients with benign pancre-
atic disease (CON01-CON15), and 16 healthy controls (H01-H20)
(Figure 3A and 3B). MSLN specific CD4+ and CD8+ T cells were
identified using intracellular cytokine staining assays for IFN-c and
representative dot plots of MSLN-specific CD4+/CD8+ T cell
responses are shown (Figure 3A). An anti-MSLN CD4+ T cell
response was observed in 84% of pancreatic cancer patients (21
out of 25), 66.7% of patients with benign disease (10 out of 15) and
43.7% of healthy donors (7 out of 15). The percentage of cancer
patients with anti-MSLN T cell response (responders) was
significantly higher than that in healthy donors (p = 0.014, x2
test). Anti-MSLN CD8+ T cell responses were detected in 36% of
cancer patients (9 out of 25), 20% of benign pancreatic disease
patients (3 out of 15) and in only 6.3% of healthy controls (1 out of
16). The number of peptide pools stimulating antigen specific IFN-
c production by CD4+ or CD8+ T cells in 25 patients with
pancreatic cancer, 15 patients with benign pancreatic disease and
16 healthy donors are shown (Figure 3B). On average, each cancer
patient responded to 2.3 MSLN peptide pools, which was higher
than that in patients with benign pancreatic disease (1.2 MSLN
peptide pools) and healthy controls (0.7 MSLN peptide pool,
p,0.001, one-way ANOVA).
MSLN-specific CD4+ T cell responses are expanded in
patients with pancreatic carcinoma
The frequency of antigen specific IFN-c producing CD4+ T
cells recognizing MSLN-peptide pools were analysed using an
intracellular cytokine staining assay. The percentage of MSLN-
specific IFN-c producing CD4+ T cells for healthy donors (H01-
H16, n= 16), benign pancreatic disease patients (CON01-
CON15, n= 15) and pancreatic cancer patients (P01-PC25,
n = 25) are shown in Figure 4A. The results demonstrate that
the frequency of circulating anti-MSLN specific CD4+ T cells in
cancer patients were significantly higher than that observed in the
benign pancreatic disease patients (p = 0.0053) and normal
controls (p = 0.0004, Figure 4B).
CD4+ T cell responses to all 7 different peptide pools were
detected in cancer patients. CD4+ T cells recognizing peptide pool
1 was detected in larger number of patients (14 out of 25 patients)
than CD4+ T cells recognizing other peptide pools. No CD4+ T
cell response recognizing peptide pool 1 was detected in healthy
controls (Figure 5A). There was no correlation between the levels
of serum MSL and the frequency of MSLN-specific T cell
responses (data not shown). In general, the results imply that T cell
responses in cancer patients are directed toward a broad repertoire
of epitopes within MSLN protein.
Identification of immunogenic MSLN peptides
To further identify the specific peptides within the peptide pools
recognized by the T cells, we assessed IFN-c production by CD4+
and/or CD8+ T cells after short term stimulation of T cell lines
with individual peptides from various peptide pools. Among the
responders, PBMCs from 10 pancreatic cancer (PC01, PC02,
PC13, PC17, PC18, PC19, PC22, PC23, PC24, PC25), 6 benign
pancreatic disease patients (CON01, CON02, CON04, CON09,
CON 10, CON11), and 1 healthy volunteer (H02) were available
for further studies. The specific peptide epitope which induced
CD4+ or CD8+ T cell responses are shown in Table 4. It should be
noted that very few cells were available for individual peptide
analysis from the patients or healthy controls. For example,
PBMCs from PC23 were only sufficient to analyse individual
peptides within pool 6, but not pool 7. In other cases, we were
unable to identify the reacting individual peptides from some
patients, including PC02 (reacting to pool 7), because of weak
IFN-c signal with individual peptides. However, cells were
available from H02, the only healthy donor with response to pool
7, thus we were able to identified the reacting peptides recognized
by PBMCs from this individual (Table 4). CD4 T cells recognized
the identified peptide and produced IFN-c in a dose dependent
manner (data not shown). Some peptides were subsequently
analyzed for their ability to stimulate intracellular IL-2, TNF-aand
TNF-cproduction. The FACS plots shown (Figure 5B) indicate
that the CD4+ T cells were functional, antigen-specific and able to
generate both IL-2 and TNF-a.
IL-10 blockade enhances MSLN-specific IFN-c production
by CD4+ and CD8+ T cells
IL-10 is an important immunosuppressive cytokine detected in
many cancer patients and has the ability to modulate anti-tumour
immunity. Since IL-10 levels were significantly elevated in the
circulation of pancreatic cancer patients compared to the controls,
we tested the influence of IL-10 blockade on the ability of MSLN-
specific T cells to produce IFN-c. PBMCs from 7 patients with
pancreatic cancer and 2 patients with benign pancreatic disease
were peptide-stimulated in the presence of anti-IL-10 and anti-IL-
10 receptor blocking antibodies (added to the cultures on day 1
and 4). T cell lines were re-stimulated with irrelevant or relevant
peptide pools prior to intracellular cytokine staining for IFN-c
secretion. Representative dot plots of IFN-c production by CD4+
or CD8+T cells following IL-10 blockage are shown in Figure 6A.
After peptide stimulation in the presence of anti-IL10 blockade,
the frequency of MSLN-specific CD8+ T cells was increased in
PBMC of 2 out of 7 patients with pancreatic cancer.. Similarly,
PBMC from 4 out of 9 patients demonstrated an increased
frequency of MLSN-specific IFN-c producing CD4+ T cells after
Figure 4. The frequencies of MSLN-specific IFN- c producing CD4 T cells are shown for healthy donors (H01-H16, n=16), patients
with benign pancreatic disease (CON 01-CON15, n=15) and patients with pancreatic carcinoma (PC01-PC25, n=25). T cell lines were
stimulated with seven different peptide pools and the frequencies of IFN- c producing CD4 T cells were analysed using intracellular cytokine staining
assays (A). Each symbol represents the percentage of MSLN peptide pool-induced IFN-c producing CD4+ T cells in healthy controls, benign pancreatic
disease patients (benign) and patients with pancreatic carcinoma (B). Mann-Whitney U test was used to compare the percentages of CD4 T cell
response in the different groups.
doi:10.1371/journal.pone.0088133.g004
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IL-10 blockage (Figure 6B). The results demonstrate that the
percentages of IFN-c producing CD4+ T cells were significantly
increased in the presence of the blocking antibodies (p = 0.04).
These results suggest that the blockade of IL-10 may restore or
promote IFN-c production in MSLN-specific T cells isolated from
patients with pancreatic cancer.
Discussion
The prognosis for patients with pancreatic cancer remains
extremely poor and novel treatment such as T cell based
immunotherapy are required to improve survival rate. MSLN is
a tumour associated antigen in pancreatic cancer and is a target
for immunotherapy. There is little information on the status of
naturally occurring MSLN-specific CD4+ and CD8+ T cell
responses in cancer patients. Here, we aimed to assess naturally
occurring T cell responses to MSLN in cancer and benign
pancreatic disease patients and establish whether there is any
possible association between MSLN-T cell responses and the levels
of plasma MSLN or cytokines.
MSLN is expressed in more than 90% of pancreatic tumour
tissues as demonstrated by immunohistochemistry [26–28]. To our
knowledge, only one study [31] to date have reported the elevation
of circulating MSLN in pancreatic cancer patients compared to
healthy controls. Compared to their performance, our study
increased the number of healthy and benign pancreatic disease
controls, which were considered as risk factors for pancreatic
cancer. Meanwhile, majority of the malignant subjects were
recruited when the biopsy specimen for diagnosis was taken, which
means these patients have not been firmly diagnosed as pancreatic
cancer and not received related treatment when we collected the
blood samples. Our results confirmed their data and demonstrated
that soluble MSLN levels are increased in the plasma of cancer
patients and benign pancreatic disease patients compare to that in
healthy donors. Similar to their results [31], we could not observe
any significant differences in plasma MSLN levels between cancer
and benign pancreatic disease patients. However, the mean
concentration of MSLN identified in the cancer group was higher
than in the benign disease groups.
Elsewhere, elevated serum cytokines and/or chemokines have
been observed in cancer patients (such as TNF-a and IL-6), whilst
others, like IL-12, are often down-regulated [37]. Here, we focused
on the plasma concentration of IL-10, which is regarded as an
immune-regulatory cytokines and has the ability to suppress T cell
function [38,39]. The elevation of circulating IL-10 had been
previously reported in some cancer patients [40]. Current reports
state that circulating IL-10 levels were increased in pancreatic
carcinoma compared to healthy controls [41]. To identify whether
the levels of IL-10 are increased in pancreatic cancer patients
compared to benign pancreatic disease patients, we measured the
concentration of this cytokine, known to modulate tumour-specific
T cell responses, in the plasma of 34 PC patients, 15 patients with
benign pancreatic disease and 13 healthy donors. Consequently,
plasma concentrations of IL-10, the important tumour suppressive
cytokine, were elevated in PC patients (statistically significant)
compared to that of both healthy and benign controls. Thus, our
study has further demonstrated that circulating IL-10 levels were
significantly increased in pancreatic cancer patients compared to
patients with benign pancreatic diseases. Here, we have also
shown that mesothelin is increased in benign pancreatic disease
patients as compared to healthy donors and IL-10 can inhibit
MSLN-specific CD4 T cell responses. These results may suggest
that there is possibility of inducing autoimmune pancreatitis by
expression of mesothelin in this group of patients. As circulating
MSLN was increased in both cancer patients and benign patients,
it is possible that pancreatic inflammation and inflammatory
mediators can induce MSLN. Further studies are required to
evaluate whether inflammatory mediators are able to enhance
MSLN expression by pancreatic cells.
We could not establish any association between the levels of
elevated plasma IL-10 and the presence or intensity of MSLN-
specific T cell responses (data not shown). As we only collected the
plasma samples on a single time point, we are not able to describe
the change of plasma levels of MSLN and IL-10 during the
Figure 5. MSLN-specific CD4+ T cell responses in patients with pancreatic carcinoma. The frequencies of IFN-c producing CD4+ T cells
recognizing seven different MSLN-peptide pools are shown in healthy controls, patients with benign pancreatic disease and patients with pancreatic
carcinoma, (A). MSLN-specific CD4+ T cells recognize MSLN-derived peptides and produced IFN-c, IL-2 and TNF-a as detected using intracellular
cytokine staining assay (B).
doi:10.1371/journal.pone.0088133.g005
Table 4. Identified individual reacting peptides.
Peptide
pool Peptide No sequence Response type and positive rate Positive Sample ID
Pool 1 Peptide 3 MSLN21–35 LLFLLFSLGWVGPSR CD4 response, positive 4 out of 9 PC patients
(44%), and 2 out of 5 (40%) benign patients
PC01, PC13, PC17, PC18, CON
02, CON04
CD8 response, positive 1 in 9 (11%) PC patients PC17
Peptide 10 MSLN91–105 QKNVKLSTEQLRCLA CD4 & CD8, positive 1 in 5 (20%) benign controls;
none in PC patients
CON01
Pool 5 Peptide 41&42 MSLN401–415 VNKGHEMSPQAPRRP
MSLN411–425 APRRPLPQVATLIDR
CD4 response 1 in 2 (50%) PC patients PC25
Peptide 43 MSLN421–435 TLIDRFVKGRGQLDK CD4 response 1 in 2 (50%) PC patients PC 22
Pool 6 Peptide 54 MSLN531–545 FMKLRTDAVLPLTVA CD4 response, positive 2 in 3 (66%) PC patients,
negative in 1 benign control and 1 healthy control
PC23, PC24
Pool7 Peptide 60&61 MSLN591–605 PNGYLVLDLSMQEAL
MSLN601–615 MQEALSGTPCLLGPG
CD4 response, positive in 1 healthy control,
negative in 2 PC patients
H02
doi:10.1371/journal.pone.0088133.t004
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progression of pancreatic cancer based on our data. However, our
data suggested that circulating IL-10 and MSLN levels may
undergo quantitative change when malignancy had developed
compared to normal status.
Evidence from other studies have shown that detectable T cell
responses against MSLN are present in pancreatic cancer patients
[31,42], suggesting that MSLN over-expression may stimulate
clinically meaningful self-restricted T cell responses. Most studies
to date have focused on CD8+ T cell responses. However, there is
very little information on the status of CD4+ T cell responses,
known to be critical for activating and promoting antitumor CD8+
T cell memory [18]. We next tried to identify MSLN peptide pool-
specific CD8+ and CD4+ T cell responses and subsequently
individual CD4+ T cell recognised peptide epitopes using 15-mer
amino acid-long overlapping MSLN peptides. The results have
confirmed that CD4+ and CD8+ T cell responses could be
expanded in pancreatic cancer patients, and that these patients
had an increased frequency of IFN-c secreting CD4+ T cells,
compared to the controls. There was no difference in the
fluorescent intensity of IFN-c production between the groups,
suggesting that there was no difference in the amounts of cytokine
produced, by CD4+ or CD8+ T cells (data not shown). However,
further quantitative analysis of IFN-c production is required to
confirm this observation. In cancer patients, CD4+ T cell
responses were detected to all seven MSLN-derived peptide pools,
suggesting that the response is directed toward a broad repertoire
of epitopes within the MSLN protein. Another interesting
observation was that no T cell response reacting to pool one was
observed in healthy controls, while pool one was the most
immunogenic peptide pools in PC patients. Again, we didn’t
observe any association between circulating plasma MSLN levels
and CD4+ T cell responses in pancreatic cancer subjects at the
time point analysis. This is in agreement with the results
demonstrating that the levels of serum tumour associated antigens,
such as Alpha-fetoprotein (AFP) and NY-ESO-1, are not
associated with the presence of T cell responses to these antigens
[43,44]. It has been shown that, at least in some malignancies,
tumour associated antigens are expressed in tumour tissues but the
levels of the tumour associated antigens are not elevated in the
serum [45], suggesting that the levels of circulating MSLN do not
reflect the amount of MSLN at the tumour site where antigen
presenting cells and infiltrating effector T cells can be exposed to
MSLN. This may explain why there is no association between
serum MSL levels and the presence or absence of MSLN-specific
T cell responses. Further studies using the whole MSLN protein as
a stimulus are required to stimulate PBMCs and assess T cell
responses to the whole antigen. Due to limited number of cells
available, we were unable to identify the reacting peptides within
the peptide pools in all patients or healthy donors. We had access
to further PBMCs from some patients and healthy controls as
described in Material and Methods. CD4+ and CD8+ T cell
responses recognizing the individual peptides within the peptide
pools were analysed in these patients and controls. The results are
presented in Table 4. MSLN21–35 LLFLLFSLGWVGPSR was
recognized by CD4+ T cells in 5 out of 14 patients with pancreatic
cancer or benign pancreatic disease. MSLN401–415 VNKGH
EMSPQAPRRP, MSLN531–545 FMKLRTDAVLPLTVA, could
also stimulate secretion of IL-2 and TNF-c. Based on peptide-
binding motifs of HLA class II alleles deposited in the SYFPEITHI
database, MSLN21–35 is predicted to bind to HLA-DRB1*0101,
HLA-DRB1*0301, HLA-DRB1*0401, HLA-DRB1*0701, HLA-
DRB1*1101 and HLA-DRB1*1501. MSLN401–415 is predicted
to bind to HLA-DRB1*0101, HLA-DRB1*1101 and
HLA-DRB1*1501. MSLN531–545 is predicted to bind to HLA-
DRB1*0101, HLA-DRB1*0301, HLA-DRB1*0401, HLA-
DRB1*0701, HLA-DRB1*1101 and HLA-DRB1*1501.
As we observed significantly increased circulating IL-10 levels in
pancreatic cancer patients, compared to the controls, here, we
assessed the influence of IL-10 blockade on MSLN-specific T cell
responses in 9 pancreatic disease patients. The anti-IL10 blockade
(blocking both free IL-10 and IL-10 receptor) increased the
frequency of CD8+ T cell responses in 2 patients and CD4+ T cell
responses in 4 patients. This result demonstrates that IL-10 may
play a role in modulation of anti-tumour immunity in patients with
pancreatic cancer.
In conclusion, we demonstrated that MSLN was immunogenic,
reported the dominant region of MSLN required for the induction
of specific T cell responses and described an in vitro method to
promote these T cell responses, which may contribute to the
development of MSLN related immunotherapy against pancreatic
cancer.
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